Clofarabine/cyclophosphamide for debulking before stem cell transplantation

European Journal of Clinical Investigation

Volumn 44, Issue 8, 2014, Pages 775-783

  Rabitsch, Werner ^a   Böhm, Alexandra ^a   Bojic, Marija ^a   Schellongowski, Peter ^a   Wöhrer, Stefan ^a   Sliwa, Thamer ^a   Keil, Felix ^a   Worel, Nina ^a   Greinix, Hildegard ^a   Hauswirth, Alexander ^a   Kalhs, Peter ^a   Jaeger, Ulrich ^a   Valent, Peter ^a   Sperr, Wolfgang R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Debulking; Haematopoietic stem cell transplantation; Refractory leukaemia; Survival

Indexed keywords

CLOFARABINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHOTREXATE; MITOXANTRONE; VINCRISTINE; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHIMERA; CLINICAL ARTICLE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; WHOLE BODY RADIATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; DRUG ADMINISTRATION; FEMALE; GRAFT VS HOST DISEASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MORTALITY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADENINE NUCLEOTIDES; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904549904     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12294     Document Type: Article

References (40)

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62.
2. Vellenga E, Griffin JD. The biology of acute myeloblastic leukemia. Semin Oncol 1987;14:365-71.
3. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010;116:1165-76.
4. Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107:1116-23.
5. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33.
6. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-207.
7. Estey EH. Prognostic factors in acute myelogenous leukemia. Leukemia 2001;15:670-2.
8. Collins-Underwood JR, Mullighan CG. Genomic profiling of high-risk acute lymphoblastic leukemia. Leukemia 2010;24:1676-85.
9. Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol 2010;150:389-405.
10. Bacher U, Kohlmann A, Haferlach T. Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies. Cancer Treat Rev 2010;36:637-46.
11. Locke FL, Artz A, Rich E, Zhang Y, van Besien K, Stock W. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant 2010;45:1692-8.
12. Craddock C, Tauro S, Moss P, Grimwade D. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005;129:18-34.
13. Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011;25:808-13.
14. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002;43:1715-27.
15. Weltermann A, Fonatsch C, Haas OA, Greinix HT, Kahls P, Mitterbauer G et al. Impact of Cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 2004;18:293-302.
16. Fullmer A, O'Brien S, Kantarjian H, Jabbour E. Novel therapies for relapsed acute lymphoblastic leukemia. Curr Hematol Malig Rep 2009;4:148-56.
17. Doney K, Gooley TA, Joachim Deeg H, Flowers ME, Storb R, Appelbaum FR. Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006. Biol Blood Marrow Transplant 2010;17:1187-95.
18. Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA et al. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant 2005;35:965-70.
19. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5728-38.
20. Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2008;14:137-80.
21. Zwitserloot AM, Mavinkurve-Groothuis AM, Galama JM, Verweij PE, Hoogerbrugge PM, Warris A. Importance of neutropenia for development of invasive infections at various phases of treatment for hemato-oncological diseases in cildren. Scand J Infect Dis 2012;44:355-62.
22. Platzbecker U, Thiede C, Füssel M, Geissler G, Illmer T, Mohr B et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 2006;20:707-14.
23. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314:729-35.
24. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.
25. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;15:1519-38.
26. Winston DJ, Gale RP. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Bone Marrow Transplant 1991;8:7-11.
27. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation. N Engl J Med 1975;292:832-902.
28. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981;57:267-76.
29. Nollet F, Billiet J, Selleslag D, Criel A. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant 2001;28:511-8.
30. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-9.
31. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome or preremission and postremission therapy in audult acute myeloid: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-83.
32. Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M et al. A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukemia patients: a GOELAMS study. Leukemia 2011;25:939-44.
33. Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE et al. Prognostic value of FLT3 mutations among different cytogenetics subgroups in acute myeloid leukemia. Cancer 2010;117:2145-55.
34. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006;107:3481-5.
35. Rowe JM, Li X, Cassileth PA. Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group Experience. Blood 2005;106:162a.
36. Karp JE, Ricklis RM, Balakrishan K, Briel J, Greer J, Gore SD et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007;110:1762-9.
37. Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O et al. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant 2013;48:1437-43.
38. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012;119:3917-24.
39. Hasskarl J, Zerweck A, Wäsch R, Ihorst G, Bertz H, Finke J. Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft. Bone Marrow Transplant 2012;47:277-82.
40. Martino M, Fedele R, Moscato T, Ronco F. Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML. The role of hypomethylating agents. Curr Cancer Drug Targets 2013;13:661-9.